{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:12:39Z","timestamp":1777396359802,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmcl.2024.129948","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T23:46:49Z","timestamp":1725407209000},"page":"129948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification of triazolyl KAT6 inhibitors via a templated fragment approach"],"prefix":"10.1016","volume":"113","author":[{"given":"Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah B.","family":"Pawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy M.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-9837","authenticated-orcid":false,"given":"Andrew W.","family":"Buesking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129948_b0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.molonc.2012.09.005","article-title":"Chromatin remodeling in cancer: a gateway to regulate gene transcription","volume":"6","author":"Nair","year":"2012","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.bmcl.2024.129948_b0010","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/onc.2014.453","article-title":"KATs in cancer: functions and therapies","volume":"34","author":"Farria","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2024.129948_b0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/cc.6.6.4013","article-title":"The diverse biological roles of MYST histone acetyltransferase family proteins","volume":"6","author":"Thomas","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmcl.2024.129948_b0020","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1038\/sj.onc.1210608","article-title":"The MYST family of histone acetyltransferases and their intimate links to cancer","volume":"26","author":"Avvakumov","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2024.129948_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105930","article-title":"The role of MOZ\/KAT6A in hematological malignancies and advances in MOZ\/KAT6A inhibitors","volume":"174","author":"Su","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.bmcl.2024.129948_b0030","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/0008-5472.CAN-17-1388","article-title":"Histone Acetyltransferase KAT6A Upregulates PI3K\/AKT Signaling through TRIM24 Binding","volume":"77","author":"Lv","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.bmcl.2024.129948_b0035","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1128\/MCB.00055-16","article-title":"Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease","volume":"36","author":"Huang","year":"2016","journal-title":"Molecular Cell. Biology"},{"key":"10.1016\/j.bmcl.2024.129948_b0040","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1038\/onc.2015.33","article-title":"MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway","volume":"34","author":"Sheikh","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2024.129948_b0045","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/onc.2016.433","article-title":"Identification of MYST3 as a novel epigenetic activator of ER\u03b1 frequently amplified in breast cancer","volume":"36","author":"Yu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2024.129948_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238477","article-title":"KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma","volume":"15","author":"Saglam","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2024.129948_b0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bmcl.2024.129948_b0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.chembiol.2023.07.005","article-title":"Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A\/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer","volume":"30","author":"Sharma","year":"2023","journal-title":"Cell Chemical Biology"},{"key":"10.1016\/j.bmcl.2024.129948_b0065","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","article-title":"KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs","volume":"12","author":"Yan","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bmcl.2024.129948_b0070","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.7150\/thno.57455","article-title":"KAT6A, a novel regulator of \u03b2-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.bmcl.2024.129948_b0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","article-title":"Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth","volume":"560","author":"Baell","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129948_b0080","unstructured":"ClinicalTrials.gov. NCT04606446: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Bethesda (MD): National Library of Medicine (US); 2020 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606446."},{"key":"10.1016\/j.bmcl.2024.129948_b0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2023.41.16_suppl.1054","article-title":"2023 ASCO Annual Meeting","volume":"41","author":"Sommerhalder","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bmcl.2024.129948_b0090","article-title":"Fragment-based Drug Discovery: Lessons and Outlook","volume":"Vol. 67","author":"Earlonson","year":"2016","journal-title":"Series: Methods and Principles in Medicinal Chemistry"},{"key":"10.1016\/j.bmcl.2024.129948_b0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9","article-title":"A 'rule of three' for fragment-based lead discovery?","volume":"8","author":"Congreve","year":"2003","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmcl.2024.129948_b0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/ar500432k","article-title":"The chemical space project","volume":"48","author":"Reymond","year":"2015","journal-title":"Accounts of Chemical Research"},{"issue":"2","key":"10.1016\/j.bmcl.2024.129948_b0105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/ci600423u","volume":"47","author":"Fink","year":"2007","journal-title":"J Chem Inf Model."},{"key":"10.1016\/j.bmcl.2024.129948_b0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/ci000403i","article-title":"Molecular complexity and its impact on the probability of finding leads for drug discovery","volume":"41","author":"Hann","year":"2001","journal-title":"Journal of Chemical Information and Computer Sciences"},{"key":"10.1016\/j.bmcl.2024.129948_b0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmcl.2024.129948_b0120","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1073\/pnas.96.18.9997","article-title":"The maximal affinity of ligands","volume":"96","author":"Kuntz","year":"1999","journal-title":"Proceedings of the National academy of Sciences of the United States of America"},{"key":"10.1016\/j.bmcl.2024.129948_b0125","unstructured":"Bozikis Y.E.B., Brodsky O., Camerino M.A., Greasley S.E., Hoffman R.L., Kumpf R.A., Kung P., Richardson P.F., Stupple P.A., Stutton S.C. (2020). Benzisoxazole sulfonamide derivatives. WO\/2020\/254946. Dec. 24, 2020."},{"key":"10.1016\/j.bmcl.2024.129948_b0130","unstructured":"Under the assay conditions reported herein, potencies of the literature-reported KAT6 inhibitors compounds 1 and 2 were 30 nM and 9.5 nM, respectively."}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:17:27Z","timestamp":1729099047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24003500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"alternative-id":["S0960894X24003500"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129948","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of triazolyl KAT6 inhibitors via a templated fragment approach","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129948"}}